These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30954703)

  • 1. An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2.
    Connor-Robson N; Booth H; Martin JG; Gao B; Li K; Doig N; Vowles J; Browne C; Klinger L; Juhasz P; Klein C; Cowley SA; Bolam P; Hirst W; Wade-Martins R
    Neurobiol Dis; 2019 Jul; 127():512-526. PubMed ID: 30954703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluctuation Imaging of LRRK2 Reveals that the G2019S Mutation Alters Spatial and Membrane Dynamics.
    Sanstrum BJ; Goo BMSS; Holden DZY; Delgado DD; Nguyen TPN; Lee KD; James NG
    Molecules; 2020 May; 25(11):. PubMed ID: 32486414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.
    Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L
    Elife; 2020 Oct; 9():. PubMed ID: 33006315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.
    Islam MS; Nolte H; Jacob W; Ziegler AB; Pütz S; Grosjean Y; Szczepanowska K; Trifunovic A; Braun T; Heumann H; Heumann R; Hovemann B; Moore DJ; Krüger M
    Hum Mol Genet; 2016 Dec; 25(24):5365-5382. PubMed ID: 27794539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration.
    Liu Q; Bautista-Gomez J; Higgins DA; Yu J; Xiong Y
    Sci Signal; 2021 Jul; 14(693):. PubMed ID: 34315807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
    Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
    Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis.
    Heaton GR; Landeck N; Mamais A; Nalls MA; Nixon-Abell J; Kumaran R; Beilina A; Pellegrini L; Li Y; ; Harvey K; Cookson MR
    Neurobiol Dis; 2020 Jul; 141():104948. PubMed ID: 32434048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
    Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
    Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.
    Chang KH; Huang CY; Ou-Yang CH; Ho CH; Lin HY; Hsu CL; Chen YT; Chou YC; Chen YJ; Chen Y; Lin JL; Wang JK; Lin PW; Lin YR; Lin MH; Tseng CK; Lin CH
    Stem Cell Res Ther; 2021 Sep; 12(1):508. PubMed ID: 34551822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues.
    Iannotta L; Biosa A; Kluss JH; Tombesi G; Kaganovich A; Cogo S; Plotegher N; Civiero L; Lobbestael E; Baekelandt V; Cookson MR; Greggio E
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal Firing and Glutamatergic Synapses in the Substantia Nigra Pars Reticulata of LRRK2-G2019S Mice.
    Sitzia G; Skiteva O; Chergui K
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 G2019S and Parkinson's disease: insight from Neuroinflammation.
    Yao XY; Guan LN; Chen Q; Ren C
    Postgrad Med J; 2023 Dec; 100(1179):4-11. PubMed ID: 37777187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Pathways of LRRK2-G2019S/Rab10 Interaction in Dopaminergic Neurons.
    Fellgett A; Middleton CA; Munns J; Ugbode C; Jaciuch D; Wilson LG; Chawla S; Elliott CJH
    J Parkinsons Dis; 2021; 11(4):1805-1820. PubMed ID: 34250948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway.
    Albanese F; Domenicale C; Volta M; Morari M
    Biochem Soc Trans; 2022 Feb; 50(1):621-632. PubMed ID: 35225340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.